---
layout: default
title: Joint Progression Modeling (JPM): A Probabilistic Framework for Mixed-Pathology Progression
---

# Joint Progression Modeling (JPM): A Probabilistic Framework for Mixed-Pathology Progression

**arXiv**: [2512.03475v1](https://arxiv.org/abs/2512.03475) | [PDF](https://arxiv.org/pdf/2512.03475.pdf)

**ä½œè€…**: Hongtao Hao, Joseph L. Austerweil

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºè”åˆè¿›å±•æ¨¡åž‹ä»¥è§£å†³ç¥žç»é€€è¡Œæ€§ç–¾ç—…ä¸­æ··åˆç—…ç†çš„è¿›å±•å»ºæ¨¡é—®é¢˜**

**å…³é”®è¯**: `æ··åˆç—…ç†è¿›å±•å»ºæ¨¡` `æ¦‚çŽ‡æ¡†æž¶` `äº‹ä»¶æ¨¡åž‹` `ç¥žç»é€€è¡Œæ€§ç–¾ç—…` `æŽ’åºæ¨¡åž‹`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šåŸºäºŽäº‹ä»¶æ¨¡åž‹å‡è®¾å•ä¸€ç–¾ç—…ï¼Œä½†ç¥žç»é€€è¡Œæ€§ç–¾ç—…å¸¸æ¶‰åŠæ··åˆç—…ç†ï¼Œéœ€å»ºæ¨¡è”åˆè¿›å±•
2. æ–¹æ³•è¦ç‚¹ï¼šå¼•å…¥æ¦‚çŽ‡æ¡†æž¶ï¼Œå°†å•ç—…è½¨è¿¹è§†ä¸ºéƒ¨åˆ†æŽ’åºï¼Œæž„å»ºè”åˆè¿›å±•å…ˆéªŒï¼Œç ”ç©¶å¤šç§å˜ä½“
3. å®žéªŒæˆ–æ•ˆæžœï¼šåœ¨åˆæˆå®žéªŒä¸­ï¼ŒJPMæ¯”åŸºçº¿æ¨¡åž‹æå‡çº¦21%æŽ’åºå‡†ç¡®çŽ‡ï¼ŒMallowså˜ä½“ä¸ŽåŸºçº¿åœ¨ADå’ŒVaDæ··åˆç—…ç†åˆ†æžä¸­æ›´ç¬¦åˆæ–‡çŒ®

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Event-based models (EBMs) infer disease progression from cross-sectional data, and standard EBMs assume a single underlying disease per individual. In contrast, mixed pathologies are common in neurodegeneration. We introduce the Joint Progression Model (JPM), a probabilistic framework that treats single-disease trajectories as partial rankings and builds a prior over joint progressions. We study several JPM variants (Pairwise, Bradley-Terry, Plackett-Luce, and Mallows) and analyze three properties: (i) calibration -- whether lower model energy predicts smaller distance to the ground truth ordering; (ii) separation -- the degree to which sampled rankings are distinguishable from random permutations; and (iii) sharpness -- the stability of sampled aggregate rankings. All variants are calibrated, and all achieve near-perfect separation; sharpness varies by variant and is well-predicted by simple features of the input partial rankings (number and length of rankings, conflict, and overlap). In synthetic experiments, JPM improves ordering accuracy by roughly 21 percent over a strong EBM baseline (SA-EBM) that treats the joint disease as a single condition. Finally, using NACC, we find that the Mallows variant of JPM and the baseline model (SA-EBM) have results that are more consistent with prior literature on the possible disease progression of the mixed pathology of AD and VaD.

